Product Name: Ursolic acid-GLP-1(32-36)amide
Synonyms: Ursolic acid-LVKGRamide, Ursolic acid-Leu-Val-Lys-Gly-Arg-NH2,
IUPAC Name: ((1S,2R,4aS,6aS,6bR,10S,12aR,12bR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carbonyl)-L-leucyl-L-valyl-L-lysylglycyl-L-arginine-amide,
Description: GLP-1(32-36)amide (LVKGRamide), derived from the C terminus of the glucoincretin hormone GLP-1, increases basal energy expenditure, inhibits weight gain, reduces fat mass, and reduces the development of insulin resistance and hepatic steatosis when administered to diet-induced obese (DIO) mice. Ursolic acid (UA), a natural triterpene acid, is a promising anti-cancer drug due to its inhibitory effect on tumor growth and metastasis. However, clinical translation of UA is limited by its poor water solubility and low bioavailability. It is noteworthy that the C-17 amide and amino analogs of UA possessed better anticancer activity compared to the parent compound (UA). Most importantly, UA has the potential to conjugate with other anticancer drugs or be transformed into its halo derivatives since this will greatly facilitate scientists to get lead compounds in cancer drug discovery.